Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Genprex, ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

CINCINNATI (WKRC) — Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for those living with pancreatic cancer. This trial is ...

Our findings suggest that RAS amplification may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status can help clinicians identify patients who may have a reduced benefit from ...

A new study shows that targeting key epigenetic proteins may permanently switch off cancer genes. Scientists at Monash University, working with Harvard University, report they have found a way to ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...